Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

Yale University

Status and phase

Active, not recruiting

Phase 3

Phase 2

Conditions

Obesity/Overweight

Loss-of-control Eating

Treatments

Other: Placebo

Drug: Lisdexamfetamine Dimesylate (Medication)

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT04599504

2000029057b

5R01DK126637-02 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study will test the effectiveness of lisdexamfetamine medication as a treatment for loss-of-control eating and weight following bariatric surgery. This is a controlled test of whether, amongst non-responders to acute treatments, lisdexamfetamine medication results in superior outcomes compared with placebo.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Be in the age range ≥18 years of age and <65 years of age.
Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy
Approximately ten months post-surgery
Experienced regular loss of control eating about six months after bariatric surgery, and were considered treatment non-responders to a four-month treatment trial of medication and/or BWL
Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies).
Read, comprehend, and write English at a sufficient level to complete study-related materials.
Provide a signed and dated written informed consent prior to study participation.
Be available for participation in the study for up to 15 months (3-month treatment plus 12-month follow up).

Exclusion criteria

Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).
Has a history of anorexia nervosa or history of bulimia nervosa.
Is currently using other medications for weight loss.
Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute.
Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.
Has current uncontrolled hypertension.
Has current uncontrolled Type I or Type II diabetes mellitus.
Has untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit.
Has gallbladder disease.
Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder.
Is currently in active treatment for eating or weight loss.
Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
Is breast-feeding or is pregnant or is not using a reliable form of birth control.
Reports active suicidal or homicidal ideation.
Previous history of problems with LDX or other stimulants.
Has a history of allergy or sensitivity to LDX or other stimulant medications.
Current medication contraindicated with study medication.
Any current psychostimulant use or any medication for ADHD.
History or current alcohol or substance use disorder (smoking will not be exclusionary)
Is currently taking MAOI medication, SSRI medication, or strong inhibitors of CYP2D6